Gapping up
In reaction to strong earnings/guidance:
- IIVI +27.8%, BHF +14.3%, GDOT +13.6%, CDLX +10.7%, GWPH +9.9%, DDOG +9.4%, SPG +8.3%, IFF +8.3%, VOD +8.3%, PSEC +7.8%, G +7.5%, ERI +7%, MAC +6.1%, ENSG +6%, LOGI +5.8%, LOGI +5.8%, GO +5.5%, AEG +5.5%, TUFN +4.8%, KWR +3.5%, DT +3.5%, MESA +3.4%, BE +2.7%, FOE +2.6%, CZR +2.4%, AFG +2.2%, NHI +2.1%, RPAY +1.5%, ECPG +1.3%, HHC +1.2%, AMCR +0.9%, VSH +0.7%
Other news:
- CBAY +144% (provides corporate update; independent panel concludes there was no evidence of seladelpar-induced liver injury in Phase 2b NASH study)
- GMDA +63% (reports Phase 3 Clinical Study of Omidubicel met primary endpoint)
- NVAX +44.9% (announces COVID funding of up to $388 mln from CEPI to advance vaccine development; also reports Q1 earnings)
- IVR +10.3% (provides update on dividend payment, portfolio)
- PTGX +3.2% (upsizes offering by 2 mln shares and prices 7 mln shares of common stock at $14 per share)
- AKBA +2.3% (prices offering of 11 mln shares of common stock at $12.00 per share)
- TSLA +1.9% (CEO Elon Musk tweets that co "is restarting production today against Alameda County rules")
- MYOK +1.7% ($450 mln stock offering)
- AB +1% (reports month-end assets under management)
- BCYC +1% (announces publication of BT5528 mechanism of action in AACR Journal Molecular Cancer Therapeutics)
Analyst comments:
- AMRX +1.5% (upgraded to Neutral from Sell at Guggenheim)
- AXTA +1.3% (upgraded to Buy from Neutral at Goldman)
- PNW +1% (upgraded to Buy from Neutral at Guggenheim)